ZANVASTRO (Zilganersen Sodium) Patent Expiration, LOE Window & CMS Spending
ZANVASTRO (Zilganersen Sodium) by Ionis Pharmaceuticals: FDA Orange Book core substance LOE 2041-05-20, 0 AB generics, $0 2024 CMS Part D & Medicaid spend, and $285,000 CA SB 17 specialty launch WAC.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Consolidated Sponsor | Ionis Pharmaceuticals |
| FDA Application & Pathway | N220210 (NDA) |
| Exclusivity / Cliff Horizon | Long-Dated Protection (2036+) |
| Core Active-Ingredient LOE Date | 2041-05-20 |
| Last Listed Patent or Exclusivity Date | 2041-05-20 |
| Orange Book Patents (*PED Extensions) | 1 patents (0 *PED) |
| Active AB-Rated Generic Competitors | 0 |
| 2024 CMS Total Public Spend | $0 |
| 2024 Medicare Part D Spend | $0 |
| 2024 Medicaid Spend | $0 |
| Reported Wholesale Price Change (CA SB 17) | Specialty launch notice ($285,000 intro WAC) |